Syros Pharmaceuticals, Inc. (SYRS)
 OTCMKTS  · Delayed Price · Currency is USD  
0.0008
 +0.0004 (100.00%)
  Nov 3, 2025, 4:00 PM EST
Syros Pharmaceuticals Revenue
Syros Pharmaceuticals had revenue of $386.00K in the twelve months ending September 30, 2024, down -95.61% year-over-year. In the year 2023, Syros Pharmaceuticals had annual revenue of $9.94M, down -33.23%.
Revenue (ttm) 
 386.00K
Revenue Growth 
 -95.61%
P/S Ratio 
 0.06
Revenue / Employee 
 5.68K
Employees 
 68
Market Cap 
21.47K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2023 | 9.94M | -4.94M | -33.23% | 
| Dec 31, 2022 | 14.88M | -8.61M | -36.65% | 
| Dec 31, 2021 | 23.49M | 8.40M | 55.62% | 
| Dec 31, 2020 | 15.09M | 13.11M | 661.50% | 
| Dec 31, 2019 | 1.98M | -68.00K | -3.32% | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| American Oncology Network | 1.76B | 
| Veradigm | 588.02M | 
| Jushi Holdings | 256.36M | 
| Glass House Brands | 221.55M | 
| Elite Pharmaceuticals | 105.45M | 
| Silence Therapeutics | 27.17M | 
| China New Energy Group Co. | 12.51M | 
| Northwest Biotherapeutics | 1.09M | 
Syros Pharmaceuticals News
- 7 months ago - Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - Seeking Alpha
 - 8 months ago - Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration - Business Wire
 - 1 year ago - Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
 - 1 year ago - Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression - Business Wire
 - 1 year ago - The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions - Accesswire
 - 1 year ago - Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm - Accesswire
 - 1 year ago - The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations - Accesswire
 - 1 year ago - Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript - Seeking Alpha